The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula:

##STR00001##

wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atoms; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

Disclosed in the present disclosure is a Dezocine analog, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof. ##STR00001##

Disclosed in the present disclosure is a Dezocine analog, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof. ##STR00001##

The present invention discloses therapeutic compounds of the aminoindane class, including certain short-acting ester and lactone derivatives, and pharmaceutical compositions made therewith, as well as methods of their use in the treatment of alcohol and other substance use disorders, behavioral addictions, and CNS and mental health disorders, and for the improvement of mental health and psychological functioning.

The present invention discloses therapeutic compounds of the aminoindane class, including certain short-acting ester and lactone derivatives, and pharmaceutical compositions made therewith, as well as methods of their use in the treatment of alcohol and other substance use disorders, behavioral addictions, and CNS and mental health disorders, and for the improvement of mental health and psychological functioning.

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula:

##STR00001##

wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atoms; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula:

##STR00001##

wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atoms; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

Disclosed in the present disclosure is a Dezocine analogue, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.

##STR00001##

Disclosed in the present disclosure is a Dezocine analogue, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.

##STR00001##

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: ##STR00001##
wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atom; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.